Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2018-04-25 Delisting Announcement
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Publication of prospectus summary for transfer of listing to Oslo Børs
Delisting Announcement Classification · 99% confidence The document explicitly discusses the 'TRANSFER FROM OSLO AXESS TO OSLO BØRS' for PCI Biotech Holding ASA's shares, referencing compliance with Norwegian Securities Trading Regulation and detailing the listing approval date (April 25, 2018) and expected first day of listing (April 27, 2018). This type of official regulatory announcement concerning a change in stock exchange listing venue, often involving a formal document summary required by regulators, fits best under a general regulatory filing category. Since there is no specific code for 'Listing Transfer Announcement,' and it is a formal regulatory disclosure document, it falls under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like 10-K or ER. The document length is substantial (56,899 chars), suggesting it is the primary disclosure document, not just a brief announcement of publication (RPA).
2018-04-25 Norwegian
PCI Biotech: Publication of prospectus summary for transfer of listing to Oslo Børs
Report Publication Announcement Classification · 98% confidence The document explicitly states that the company has 'published a prospectus summary' in connection with a 'transfer of listing from Oslo Axess to Oslo Børs'. The text is very short (999 characters) and its primary function is to announce the availability of the prospectus summary, which is 'attached hereto' and available online. This aligns perfectly with the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports, rather than being the full prospectus itself. It is not a standard regulatory filing like 10-K or IR, nor is it a general RNS announcement, as RPA is more specific for report publication notices.
2018-04-25 English
Resolution of transfer of listing from Oslo Axess to Oslo Børs
Regulatory Filings Classification · 99% confidence The document explicitly announces the resolution for the transfer of listing of PCI Biotech Holding ASA's shares from Oslo Axess to Oslo Børs. This action relates to the company's stock exchange listing status. Among the provided definitions, 'Delisting Announcement' (DLST) covers official notices about stock removal from an exchange, which is closely related to a transfer of listing between regulated markets. While it's not a pure delisting, it is a significant change in the listing venue, making DLST the most appropriate category for major exchange status changes, or alternatively, RNS as a general regulatory announcement. Given the specific nature of changing listing venues, DLST is chosen as it pertains directly to the listing status, even if it's a transfer rather than a complete removal from all exchanges. The document is very short (485 chars), suggesting it is an announcement rather than a comprehensive report.
2018-04-25 English
PCI Biotech: Capital increase registered and listing of new shares
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces a 'Capital increase registered and listing of new shares' following the exercise of employee share options. It details the completion of the share capital increase, the new total share capital, and the expected date for the new shares to become tradable. This directly relates to changes in the company's capital structure and share count, matching the definition for Capital/Financing Update (CAP). Although it involves shares, it is not a general share repurchase (POS) but a specific capital increase event.
2018-04-17 English
PCI Biotech: Exercise of employee share options and resolution to increase the share capital
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces two related corporate actions: the 'Exercise of employee share options' and a 'resolution to increase the share capital' through the issuance of new shares. This directly relates to changes in the company's share structure and capital base. Reviewing the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate classification as it covers announcements regarding new share issues or capital structure changes. The document is a direct announcement of the event, not a general regulatory filing (RNS) or a report publication announcement (RPA).
2018-04-12 English
Application for transfer of listing to Oslo Børs
Regulatory Filings Classification · 99% confidence The document explicitly states it is an 'Application for transfer of listing to Oslo Børs'. This action relates to the company's stock exchange listing status. Reviewing the definitions, 'Delisting Announcement' (DLST) covers official notices that the stock will be removed from an exchange. While this is a *transfer* rather than a pure delisting, it is a significant change to the listing venue, which is closely related to exchange status changes. However, none of the categories perfectly match 'Transfer of Listing'. The closest related category concerning exchange status is DLST. Since this is a specific regulatory action concerning the listing venue, and it is not a standard financial report (10-K, IR, ER), nor a management change (MANG), nor a capital event (CAP, SHA), it falls best under the general regulatory/exchange action category. Given the options, DLST is the most contextually relevant category dealing with exchange status changes, although it is not a perfect fit. If a more specific 'Listing Change' code existed, it would be preferred. As a fallback for specific regulatory actions not covered, RNS (Regulatory Filings) is also possible, but DLST captures the essence of the filing better than a generic RNS.
2018-03-21 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.